A dose of 25 mg/kg, significantly improved spatial memory deficits and modulated hippocampal markers, including APP and brain-derived BDNF, in an AD rat model [126], suggesting EGCG’s potential therapeutic effects for AD. The gene discussed is APP; the disease is Alzheimer disease.